A look at the clinical, economic, and societal impact of antimicrobial resistance in 2020

References

• Brown ED, Wright GD. Antibacterial drug discovery in the resistance era. Nature. 2016;529:336–343.
   PubMed Web of Science ®Google Scholar
• Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev. 2010;74:417–433.
   PubMed Web of Science ®Google Scholar
• Abraham EP, Chain E. An enzyme from bacteria able to destroy penicillin. 1940. Rev Infect Dis. 1988;10:677–678.
   PubMedGoogle Scholar
• Fauci AS, Marston D. The perpetual challenge of antimicrobial resistance. JAMA. 2014;311:1853–1854.
   PubMed Web of Science ®Google Scholar
• Viscoli C, Varnier O, Machetti M. Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin Infect Dis. 2005;40(Suppl 4):S240–245.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Poulakou G, Ruppe E, et al. Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach. Intensive Care Med. 2017;43:1464–1475.
   PubMed Web of Science ®Google Scholar
• Courvalin P. Why is antibiotic resistance a deadly emerging disease? Clin Microbiol Infect. 2016;22:405–407.
   PubMed Web of Science ®Google Scholar
• Barriere SL. Clinical, economic and societal impact of antibiotic resistance. Expert Opin Pharmacother. 2015;16:151–153.
   PubMed Web of Science ®Google Scholar
• Allegranzi B, Kilpatrick C, Storr J, et al. Global infection prevention and control priorities 2018-22: a call for action. Lancet Glob Health. 2017;5:e1178–e1180.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Giacobbe DR, Vena A, et al. Challenges and research priorities to progress the impact of antimicrobial stewardship. Drugs Context. 2019;8:212600.
   PubMedGoogle Scholar
• Giacobbe DR, Del Bono V, Mikulska M, et al. Impact of a mixed educational and semi-restrictive antimicrobial stewardship project in a large teaching hospital in Northern Italy. Infection. 2017;45:849–856.
   PubMed Web of Science ®Google Scholar
• Hernando-Amado S, Coque TM, Baquero F, et al. Defining and combating antibiotic resistance from one health and global health perspectives. Nat Microbiol. 2019;4:1432–1442.
   PubMed Web of Science ®Google Scholar
• McEwen SA, Collignon PJ. Antimicrobial resistance: a one health perspective. Microbiol Spectr. 2018;6:ARBA-0009-2017.
   Web of Science ®Google Scholar
• Redi D, Raffaelli CS, Rossetti B, et al. Staphylococcus aureus vaccine preclinical and clinical development: current state of the art. New Microbiol. 2018;41:208–213.
   PubMed Web of Science ®Google Scholar
• Theuretzbacher U, Outterson K, Engel A, et al. The global preclinical antibacterial pipeline. Nat Rev Microbiol. 2020;18:275–285.
   PubMed Web of Science ®Google Scholar
• Hendriksen RS, Munk P, Njage P, et al. Global monitoring of antimicrobial resistance based on metagenomics analyses of urban sewage. Nat Commun. 2019;10:1124.
   PubMed Web of Science ®Google Scholar
• Wyres KL, Lam MMC, Holt KE. Population genomics of Klebsiella pneumoniae. Nat Rev Microbiol. 2020;18:344–359.
   PubMed Web of Science ®Google Scholar
• Shendure J, Balasubramanian S, Church GM, et al. DNA sequencing at 40: past, present and future. Nature. 2017;550:345–353.
   PubMed Web of Science ®Google Scholar
• Dubourg G, Raoult D, Fenollar F. Emerging methodologies for pathogen identification in bloodstream infections: an update. Expert Rev Mol Diagn. 2019;19:161–173.
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Giani T, Bassetti M, et al. Rapid microbiological tests for bloodstream infections due to multidrug resistant Gram-negative bacteria: therapeutic implications. Clin Microbiol Infect. 2020;26:713–722.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Giacobbe DR. Judging the appropriate therapy for carbapenem-resistant Acinetobacter infections. Expert Opin Pharmacother. 2020;21:135–138.
   Web of Science ®Google Scholar
• Tsuji BT, Pogue JM, Zavascki AP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39:10–39.
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Mikulska M, Viscoli C. Recent advances in the pharmacological management of infections due to multidrug-resistant gram-negative bacteria. Expert Rev Clin Pharmacol. 2018;11:1219–1236.
   PubMed Web of Science ®Google Scholar
• Pogue JM, Bonomo RA, Kaye KS. Ceftazidime/avibactam,meropenem/ vaborbactam,or both? Clinical and formulary considerations. Clin Infect Dis. 2019;68:519–524.
   PubMed Web of Science ®Google Scholar
• Berrazeg M, Jeannot K, Ntsogo Enguene VY, et al. Mutations in beta-Lactamase AmpC increase resistance of Pseudomonas aeruginosa isolates to antipseudomonal cephalosporins. Antimicrob Agents Chemother. 2015;59:6248–6255.
   PubMed Web of Science ®Google Scholar
• Shields RK, Chen L, Cheng S, et al. Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae Infections. Antimicrob Agents Chemother. 2017;61:e02097–16.
   Google Scholar
• Sun D, Rubio-Aparicio D, Nelson K, et al. Meropenem-vaborbactam resistance selection, resistance prevention, and molecular mechanisms in mutants of KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2017;61:e01694–17.
   Web of Science ®Google Scholar
• Marston HD, Dixon DM, Knisely JM, et al. Antimicrobial resistance. JAMA. 2016;316:1193–1204.
   PubMed Web of Science ®Google Scholar
• Pollock J, Low AS, McHugh RE, et al. Alternatives to antibiotics in a one health context and the role genomics can play in reducing antimicrobial use. Clin Microbiol Infect. 2020; 10.1016/j.cmi.2020.02.028.
   PubMed Web of Science ®Google Scholar
• Innovative Medicine Inititative. DRIVE AB report. Revitalizing the antibiotic pipeline: stimulating innovation while driving sustainable use and global access. 2018 [ accessed 2020 May 29]; Available at: http://drive-ab.eu/wp-content/uploads/2018/01/CHHJ5467-Drive-AB-Main-Report-180319-WEB.pdf
   Google Scholar
• Ardal C, Balasegaram M, Laxminarayan R, et al. Antibiotic development – economic, regulatory and societal challenges. Nat Rev Microbiol. 2020;18:267–274.
   PubMed Web of Science ®Google Scholar
• Mahase E. UK launches subscription style model for antibiotics to encourage new development. BMJ. 2020;369:m2468.
   PubMedGoogle Scholar
• OECD and ECDC. Antimicrobial resistance: tackling the burden in the European Union 2019 [ accessed 2020 May 27]; Available at: http://www.oecd.org/health/health-systems/AMR-Tackling-the-Burden-in-the-EU-OECD-ECDC-Briefing-Note-2019.pdf
   Google Scholar
• Review on antimicrobial resistance. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. 2016 [ accessed 2020 May 27]; Available at: https://amr-review.org/
   Google Scholar
• Gandra S, Barter DM, Laxminarayan R. Economic burden of antibiotic resistance: how much do we really know? Clin Microbiol Infect. 2014;20(10):973–980.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Giacobbe DR, Aliberti S, et al. Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian society of Pulmonology (SIP). Clin Microbiol Infect. 2020;26(7):880–894. .
   Web of Science ®Google Scholar
• Cilloniz C, Dominedo C, Torres A. Multidrug resistant gram-negative bacteria in community-acquired pneumonia. Crit Care. 2019;23:79.
   PubMed Web of Science ®Google Scholar
• van Duin D, Paterson DL. Multidrug-resistant bacteria in the community: trends and lessons learned. Infect Dis Clin North Am. 2016;30:377–390.
   PubMed Web of Science ®Google Scholar
• Hsu J. How COVID-19 is accelerating the threat of antimicrobial resistance. BMJ. 2020;369:m1983.
   PubMedGoogle Scholar
• Rawson TM, Moore LSP, Castro-Sanchez E, et al., COVID-19 and the potential long-term impact on antimicrobial resistance. J Antimicrob Chemother. 2020;75(7):1681–1684.
   PubMed Web of Science ®Google Scholar
• Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513.
   PubMed Web of Science ®Google Scholar
• Rawson TM, Moore LSP, Zhu N, et al. Bacterial and fungal co-infection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020; DOI:10.1093/cid/ciaa530.
   PubMed Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062.
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Battaglini D, Ball L, et al. Bloodstream infections in critically ill patients with COVID-19. Eur J Clin Invest. 2020;e13319. DOI:10.1111/eci.13319
   PubMed Web of Science ®Google Scholar
• Rawson TM, Ming D, Ahmad R, et al. Antimicrobial use, drug-resistant infections and COVID-19. Nat Rev Microbiol. 2020;18:409–410.
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Mora S, Giacomini M, et al. Machine learning and multidrug-resistant gram-negative bacteria: an interesting combination for current and future research. Antibiotics (Basel). 2020;9:54.
   Web of Science ®Google Scholar
• Prosperi M, Guo Y, Sperrin M, et al. Causal inference and counterfactual prediction in machine learning for actionable healthcare. Nature Mach Intell. 2020;2:369–375.
   Google Scholar